about
Validation of the Official Slovak Version of the Unified Dyskinesia Rating Scale (UDysRS).An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)Independent Spanish Validation of the Unified Dyskinesia Rating Scale.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.Promising therapeutic agents for the treatment of Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management.A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Verification of a Method for Measuring Parkinson's Disease Related Temporal Irregularity in Spiral Drawings.Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need.How Efficient Is Subthalamic Deep Brain Stimulation in Reducing Dyskinesia in Parkinson's Disease?Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
P2860
Q35855437-951F1967-9F1E-42EF-867D-9009D7E7BE63Q36376607-5CD1A11F-7333-477C-983F-2EE024582DB3Q37257345-4B2E27F9-05A3-4121-AC16-C23B062BEE3EQ37441475-973901B1-6B29-4A30-8736-E010DEB8B125Q38262418-E953ACA9-F3CF-43AC-8804-9442D44B3AF6Q38375701-FF347050-1B28-46A5-8BBF-B32B34AA35FCQ38767711-0CB0397C-14BE-47AA-9C65-2AA662137833Q38811387-CFBE6669-A020-48A2-ABBB-8CAEC6299947Q41626118-A5FD751A-8717-470F-BC77-6E5B4563A446Q45961748-FBB69182-FCDE-4C1A-8902-E401CC340882Q46059323-52240C98-8BA4-4112-9DFB-32DAE33DAEEAQ46641045-7DC09AAA-7D72-41E6-BA4A-69730FE1A10EQ46773863-1B28C6AD-1C38-45DB-BE69-59A5DD0049FAQ48050563-3DD8447B-1493-46B5-A661-CD28EEF8BD04Q50222039-38095BFE-FD1A-4B4E-A737-4CB43C73AAF7Q52099349-79961BE7-1BBE-47FC-A877-047711DDA500Q57113178-F23F74FE-334D-46EA-808E-6DBAEFF407F2
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Which dyskinesia scale best detects treatment response?
@en
Which dyskinesia scale best detects treatment response?
@nl
type
label
Which dyskinesia scale best detects treatment response?
@en
Which dyskinesia scale best detects treatment response?
@nl
prefLabel
Which dyskinesia scale best detects treatment response?
@en
Which dyskinesia scale best detects treatment response?
@nl
P2093
P2860
P50
P356
P1433
P1476
Which dyskinesia scale best detects treatment response?
@en
P2093
Alison Urkowitz
Anthony P Nicholas
Glenn T Stebbins
Jean A Jaglin
Kathryn A Chung
Mark A Stacy
P2860
P304
P356
10.1002/MDS.25321
P407
P50
P577
2013-02-06T00:00:00Z